Navigation Links
Researchers find potential solution to melanoma's resistance to vemurafenib
Date:2/28/2012

TAMPA, Fla. -- Researchers at Moffitt Cancer Center in Tampa, Fla., and colleagues in California have found that the XL888 inhibitor can prevent resistance to the chemotherapy drug vemurafenib, commonly used for treating patients with melanoma.

Vemurafenib resistance is characterized by a diminished apoptosis (programmed cancer cell death) response. According to the researchers, the balance between apoptosis and cell survival is regulated by a family of proteins. The survival of melanoma cells is controlled, in part, by an anti-apoptotic protein (Mcl-1) that is regulated by a particular kind of inhibitor.

Their current findings, tested in six different models of vemurafenib resistance and in both test tube studies and in melanoma patients, demonstrated an induced apoptosis response and tumor regression when the XL888 inhibitor restored the effectiveness of vemurafenib.

The study appeared in a recent issue of Clinical Cancer Research, a publication of the American Association for Cancer Research.

"The impressive clinical response of melanoma patients to vemurafenib has been limited by drug resistance, a considerable challenge for which no management strategies previously existed," said study co-author Keiran S. M. Smalley, Ph.D., of Moffitt's departments of Molecular Oncology and Cutaneous Oncology. "However, we have demonstrated for the first time that the heat shock protein-90 (HSP90) inhibitor XL888 overcomes resistance through a number of mechanisms."

The diversity of resistance mechanism has been expected to complicate the design of future clinical trials to prevent or treat resistance to inhibitors such as vemurafenib.

"That expectation led us to hypothesize that inhibitor resistance might best be managed through broadly targeted strategies that inhibit multiple pathways simultaneously," explained Smalley.

The HSP90 family was known to maintain cancer cells by regulating cancer cells, making it a good target for treatment. According to the authors, the combination of vemurafenib and XL888 overcame vemurafenib resistance by targeting HSP90 through multiple signaling pathways.

There was already evidence that HSP90 inhibitors could overcome multiple drug chemotherapy resistance mechanisms in a number of cancers, including non-small lung cancer and breast cancer. Because XL888 is a novel, orally available inhibitor of HSP90, the researchers hoped that it would arrest the cancer cell cycle in melanoma cell lines.

In their study, the inhibition of HSP90 led to the degradation of the anti-apoptopiuc Mcl-1 protein. The responses to XL888 were characterized as "highly durable with no resistant colonies emerging following four weeks of continuous drug treatment." In other studies not using XL888, resistant colonies "emerged in every case," they reported.

"We have shown for the first time that all of the signaling proteins implicated in vemurafenib resistance are 'clients' of HSP90 and that inhibition of HSP90 can restore sensitivity to vemurafenib," concluded Smalley and his colleagues. "Our study provides the rationale for the dual targeting of HSP90 with XL888 and vemurafenib in treating melanoma patients in order to limit or prevent chemotherapy resistance."


'/>"/>
Contact: Ferdie De Vega
Ferdinand.DeVega@moffitt.org
813-745-7858
H. Lee Moffitt Cancer Center & Research Institute
Source:Eurekalert

Related medicine news :

1. Kessler Foundation researchers present at DC Conference on Race, Ethnicity and Disabilities
2. Researchers Spot Genes Behind Macular Degeneration
3. 90 percent of firefighters exhibit symptoms of PTSD according to Ben-Gurion University researchers
4. New blood test for early cancer detection developed by Ben-Gurion University researchers
5. UC Davis MIND Institute researchers to present on autism at AAAS Annual Meeting in Vancouver
6. Nasty superbug is being studied by UB researchers
7. Researchers see differences in Autism brain development as early as 6 months
8. As diabetes emerges, researchers track diseases first steps
9. Salk researchers find new drug target for lung cancer
10. GW researchers reveal digital transcriptome of breast cancer
11. PRP treatment aids healing of elbow injuries say researchers
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/31/2016)... MN (PRWEB) , ... May 31, 2016 , ... DDL, ... the American Association for Laboratory Accreditation (A2LA) to include ISO 594-1 and ISO 594-2 ... common means of achieving a leak-free connection between two medical devices (e.g. a syringe ...
(Date:5/31/2016)... ... May 31, 2016 , ... Like jewels in a crown, the multiple awards ... is home to Ontario’s leading day spa and one of Canada’s few accredited 5 ... a unique concept to combine spa services with hair and beauty services ...
(Date:5/31/2016)... ... May 31, 2016 , ... The Orthopaedic Research and Education Foundation (OREF) ... David G. Lewallen, MD, began his term as president in March, succeeding John J. ... is OREF’s new president-elect. Richard F. Kyle, MD, will serve as chair, corporate development, ...
(Date:5/31/2016)... ... May 31, 2016 , ... ... 2016 Cool Vendors in Security Infrastructure Protection report by Gartner1 Inc. , Each ... series of research reports evaluating these innovative vendors and their products and services. ...
(Date:5/31/2016)... , ... May 31, 2016 , ... Super Powder, a ... to on the go individuals and dedicated athletes, continues to transform the nutritional supplement ... with whey, pea and milk protein, branched-chain amino acids (BCAA), alkaline minerals, wheat grass, ...
Breaking Medicine News(10 mins):
(Date:5/26/2016)... 26, 2016   Change Healthcare , ... network solutions and technology-enabled services designed to ... into a strategic channel partnership with SourceMed, ... solutions and revenue cycle management services that ... rehabilitation clinics to optimize revenue, operational efficiency ...
(Date:5/25/2016)... FDA 510(k) clearance covers Confocal Miniprobes ... and surgical applications Mauna Kea Technologies ... multidisciplinary confocal laser endomicroscopy (CLE) platform, today announced ... the 12 th 510(k) clearance from United ... FDA clearance covers Confocal Miniprobes indicated for use ...
(Date:5/25/2016)... Deutschland und GERMANTOWN, Maryland , ... Zusammenarbeit mit Therawis bedient dringenden ...   QIAGEN N.V. (NASDAQ: ... bekannt, eine Lizenz- und Entwicklungsvereinbarung mit Therawis Diagnostics ... die Onkologie eingegangen zu sein. Ein erstes Projekt ...
Breaking Medicine Technology: